Financial Data and Key Metrics Changes - The company reported adjusted earnings per share of $1.2, with a neutralized increase of approximately 5% over the prior year period when accounting for currency effects and tax [4][15] - Reported sales decreased by 3%, with core sales remaining flat compared to the prior year period [14] - Adjusted EBITDA increased by 3% to $183 million, with adjusted diluted earnings per share at $1.2 compared to $1.22 in the prior year [14][15] Business Line Data and Key Metrics Changes - Pharma segment's core sales increased by 3%, with prescription core sales up 10% driven by strong demand for emergency medicines and therapeutics [16] - Consumer Healthcare core sales decreased by 10% due to softer demand for nasal decongestants and cough medicines [16] - Injectables core sales decreased by 8% due to tough comparisons from the prior year, while Active Materials Science solutions saw an 11% increase in core sales [16][18] - Beauty segment's core sales decreased by 3%, with prestige fragrance and facial skincare sales down 11% [19] - Closures segment's core sales decreased by 2%, with product sales growth offset by lower tooling sales [20] Market Data and Key Metrics Changes - The U.S. market showed signs of inventory normalization, while other regions have not yet experienced similar trends [6][37] - The company noted strong demand for GLP-1 and biologics in the injectables market, indicating robust order books [7][36] Company Strategy and Development Direction - The company is focused on long-term growth driven by macro trends such as healthcare decentralization and the growth of generic medicines [6][7] - The company is ramping up share repurchases, having repurchased over $80 million worth of shares in the first quarter [13] - The company emphasizes sustainability as a competitive advantage, having received multiple awards for its efforts [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in growth prospects despite current economic uncertainties, highlighting resilience in essential product markets [28][30] - The company anticipates a strong second quarter with positive contributions from all segments, particularly in Pharma and Beauty [30][31] - Management acknowledged the evolving tariff situation but expects limited net effects on operations [25][82] Other Important Information - The effective tax rate for the first quarter was 25.8%, reflecting a temporary surtax enacted in France [15] - Free cash flow for the quarter was $26 million, with a strong balance sheet showing a cash balance of $126 million [23][24] Q&A Session Summary Question: Insights on order patterns and inventory levels - Management noted a reacceleration in orders across various segments, with U.S. inventories normalizing but not yet seen in other regions [35][37] Question: Impact of GLP-1s on injectables - Strong demand for GLP-1s is noted, with the company ramping up capabilities to meet this demand [36] Question: Tax rate guidance for the second half of the year - The expected effective tax rate for the second half is projected to be in the range of 22% to 24% [43] Question: Inventory status in cold and cough products - Management indicated that the U.S. has seen some inventory normalization, while other regions have not yet experienced this [48][49] Question: Outlook for tooling activity - Management expressed optimism about tooling activity, indicating it is on the rise as customers seek to differentiate their products [105]

AptarGroup (ATR) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.45%. A quarter ago, it was expected that this maker of consumer-product dispensing systems would post earnings of $1.26 per share when it actually produced earnings of $1.52, delivering a surprise of 20.63%.Over the la ...

May 2, 2025 Q1 2025 Results Stephan B. Tanda, Aptar President and CEO Vanessa Kanu, Executive Vice President and CFO Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs and assumptions in light of information currently available to managem ...

Exhibit 99.1 Crystal Lake, Illinois, May 1, 2025 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. First Quarter 2025 Highlights (compared to the prior year quarter) "Our pharma and closures segments delivered solid results with increased product sales in the quarter. We saw growing ...

PRINCETON, N.J., May 1, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated Breakthrough Device.  DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping the antiplatelet drug Brilinta® (ticagrelor, AstraZene ...

Wall Street expects a year-over-year decline in earnings on lower revenues when AptarGroup (ATR) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 1. On the oth ...

Group 1 - AptarGroup, Inc. is expected to benefit from growth in its Pharma and Closure segments, while facing challenges in the Beauty segment in the upcoming quarters [1] - The company focuses on GARP (Growth at Reasonable Price) opportunities within the industrial, consumer, and technology sectors [1]

Core Viewpoint - Technip Energies has secured a significant contract for the Blue Point Number One ATR Project, which aims to establish the world's largest low-carbon ammonia plant with a capacity of approximately 1.4 million metric tons per year [1][3]. Group 1: Project Details - The Blue Point Number One ATR Project is a collaboration between CF Industries, JERA, and MITSUI & CO, focusing on low-carbon ammonia production [1]. - Technip Energies will handle engineering, procurement, equipment, and module fabrication, utilizing its expertise in modularization and project delivery [2]. - The project is expected to achieve over 95% CO2 recovery, marking a significant advancement for the ammonia industry [3]. Group 2: Technological Integration - Technip Energies will integrate Topsoe's SynCOR AmmoniaTM technology into the project, showcasing its capability to incorporate advanced technologies into large-scale industrial projects [2][3]. - The low-carbon ammonia produced will cater to anticipated strong global demand for various applications, including energy and marine fuels [3]. Group 3: Company Insights - Arnaud Pieton, CEO of Technip Energies, emphasized the company's role in delivering large-scale facilities that incorporate state-of-the-art technologies, contributing to global decarbonization efforts [4]. - Technip Energies is recognized as a global technology and engineering leader, with a revenue of €6.9 billion in 2024, focusing on critical markets such as energy and decarbonization [5][6].

Core Viewpoint - AptarGroup, Inc. reported strong fourth-quarter 2024 adjusted earnings per share (EPS) of $1.52, exceeding expectations and reflecting a 27% year-over-year increase from $1.20 per share [1][2] Financial Performance - Total revenues for Q4 2024 increased by 1.1% year over year to $848 million, but fell short of the Zacks Consensus Estimate of $858 million [3] - Adjusted operating income rose 10.8% year over year to $127.5 million, with an adjusted operating margin of 15%, up from 13.7% in the prior year [4] - Adjusted EBITDA increased by 8.6% year over year to $194.9 million, with an adjusted EBITDA margin of 23% compared to 21.4% in Q4 2023 [5] Segment Performance - Pharma segment revenues grew by 4.1% year over year to $400.7 million, although it missed the estimate of $412 million [6] - Beauty segment revenues decreased by 4.8% year over year to $274 million, impacted by lower tooling sales [8] - Closures segment revenues rose by 4.6% year over year to $173 million, with core sales increasing by 7% [10] Cash Position and Shareholder Returns - As of December 31, 2024, cash and cash equivalents stood at $223.8 million, with cash flow from operations reaching $643 million for the year [12] - The board authorized a $500 million common stock repurchase and declared a quarterly cash dividend of 45 cents per share [12][13] Annual Performance - For the full year 2024, adjusted EPS increased by 17.7% year over year to $5.65, surpassing the Zacks Consensus Estimate of $5.38 [14] - Total revenues for 2024 rose by 2.7% year over year to $3.58 billion, missing the consensus estimate of $3.6 billion [14] Outlook - The company anticipates first-quarter 2025 adjusted EPS to be in the range of $1.11-$1.19 [15] Stock Performance - ATR shares have gained 4% over the past year, compared to the industry's growth of 9.5% [16]

Core Insights - AptarGroup's international revenue performance is crucial for assessing its financial resilience and growth prospects [1][2][3] Revenue Performance - The total revenue for AptarGroup in the quarter was $848.09 million, reflecting a year-over-year increase of 1.2% [4] - Latin America generated $67.16 million, accounting for 7.92% of total revenue, which was a decrease of 2.25% from the projected $68.71 million [5] - Asia contributed $94.51 million, representing 11.14% of total revenue, exceeding the consensus estimate of $89.99 million by 5.02% [6] Future Revenue Forecasts - Analysts project AptarGroup's total revenue for the current fiscal quarter to be $920.38 million, indicating a 0.5% increase from the previous year [7] - For the full year, total annual revenue is expected to reach $3.76 billion, marking a 5% increase compared to last year, with Latin America and Asia projected to contribute 8% ($300.62 million) and 10.3% ($385.55 million) respectively [8] Market Dynamics - The reliance on international markets presents both opportunities and challenges for AptarGroup, making it essential to monitor international revenue trends for future projections [9] - Analysts closely observe these trends, especially in light of global interdependence and geopolitical issues, which can influence earnings forecasts [10] Stock Performance - Over the past month, AptarGroup's stock has declined by 6.7%, while the Zacks S&P 500 composite increased by 2.1% [13] - In the last three months, the company's stock price has decreased by 14%, contrasting with a 1.2% rise in the S&P 500 index [13]